These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

103 related items for PubMed ID: 12954065

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Introduction of a putative dopaminergic prodrug moiety into a 6,7-substitution pattern characteristic of certain 2-aminotetralin dopaminergic agonists.
    Cannon JG, True CD, Long JP, Bhatnagar RK, Leonard P, Flynn JR.
    J Med Chem; 1989 Sep; 32(9):2210-4. PubMed ID: 2570153
    [Abstract] [Full Text] [Related]

  • 25. Synthesis and biological characterization of novel hybrid 7-[[2-(4-phenyl-piperazin-1-yl)-ethyl]-propyl-amino]-5,6,7,8-tetrahydro-naphthalen-2-ol and their heterocyclic bioisosteric analogues for dopamine D2 and D3 receptors.
    Dutta AK, Venkataraman SK, Fei XS, Kolhatkar R, Zhang S, Reith ME.
    Bioorg Med Chem; 2004 Aug 15; 12(16):4361-73. PubMed ID: 15265488
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease?
    Lane EL, Cheetham SC, Jenner P.
    Exp Neurol; 2006 Feb 15; 197(2):284-90. PubMed ID: 16005456
    [Abstract] [Full Text] [Related]

  • 28. Pituitary adenylate cyclase activating polypeptide protects dopaminergic neurons and improves behavioral deficits in a rat model of Parkinson's disease.
    Reglodi D, Lubics A, Tamás A, Szalontay L, Lengvári I.
    Behav Brain Res; 2004 May 05; 151(1-2):303-12. PubMed ID: 15084446
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. 3,4-Methylenedioxymethamphetamine counteracts akinesia enantioselectively in rat rotational behavior and catalepsy.
    Lebsanft HB, Kohles T, Kovar KA, Schmidt WJ.
    Synapse; 2005 Mar 01; 55(3):148-55. PubMed ID: 15602749
    [Abstract] [Full Text] [Related]

  • 31. Design, synthesis and biological evaluation of glutathione peptidomimetics as components of anti-Parkinson prodrugs.
    More SS, Vince R.
    J Med Chem; 2008 Aug 14; 51(15):4581-8. PubMed ID: 18651729
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. The differences between high and low-dose administration of VEGF to dopaminergic neurons of in vitro and in vivo Parkinson's disease model.
    Yasuhara T, Shingo T, Muraoka K, wen Ji Y, Kameda M, Takeuchi A, Yano A, Nishio S, Matsui T, Miyoshi Y, Hamada H, Date I.
    Brain Res; 2005 Mar 15; 1038(1):1-10. PubMed ID: 15748867
    [Abstract] [Full Text] [Related]

  • 35. A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson's disease.
    Tomiyama M, Kimura T, Maeda T, Kannari K, Matsunaga M, Baba M.
    Neurosci Res; 2005 Jun 15; 52(2):185-94. PubMed ID: 15893579
    [Abstract] [Full Text] [Related]

  • 36. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
    Fleming SM, Delville Y, Schallert T.
    Behav Brain Res; 2005 Jan 30; 156(2):201-13. PubMed ID: 15582106
    [Abstract] [Full Text] [Related]

  • 37. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation.
    Darmopil S, Martín AB, De Diego IR, Ares S, Moratalla R.
    Biol Psychiatry; 2009 Sep 15; 66(6):603-13. PubMed ID: 19520364
    [Abstract] [Full Text] [Related]

  • 38. Piperazinyl oxime ethers as NK-1 receptor antagonists.
    van den Hoogenband A, van Maarseveen JH, McCreary AC, Mulder AT, van Scharrenburg GJ, van Stuivenberg HH, Zethof TJ, Zijta B, Iwema Bakker WI.
    Bioorg Med Chem Lett; 2006 Feb 15; 16(4):1045-8. PubMed ID: 16289817
    [Abstract] [Full Text] [Related]

  • 39. Loss of synaptic D1 dopamine/N-methyl-D-aspartate glutamate receptor complexes in L-DOPA-induced dyskinesia in the rat.
    Fiorentini C, Rizzetti MC, Busi C, Bontempi S, Collo G, Spano P, Missale C.
    Mol Pharmacol; 2006 Mar 15; 69(3):805-12. PubMed ID: 16365282
    [Abstract] [Full Text] [Related]

  • 40. Evaluation of rat striatal L-dopa and DA concentration after intraperitoneal administration of L-dopa prodrugs in liposomal formulations.
    Di Stefano A, Carafa M, Sozio P, Pinnen F, Braghiroli D, Orlando G, Cannazza G, Ricciutelli M, Marianecci C, Santucci E.
    J Control Release; 2004 Sep 30; 99(2):293-300. PubMed ID: 15380638
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.